SAM
SPRY icon

Sectoral Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Sectoral Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
29,900
-49,250
-62% -$424K 0.17% 76
2026
Q1 		$677K Buy
79,150
+49,347
+166% +$473K 0.56% 48
2025
Q4 		$347K Sell
29,803
-51,982
-64% -$506K 0.28% 66
2025
Q3 		$822K Buy
81,785
+16,000
+24% +$230K 0.51% 56
2025
Q2 		$1.15M Sell
65,785
-34,420
-34% -$497K 0.76% 45
2025
Q1 		$1.26M Sell
100,205
-5,802
-5% -$69.8K 0.98% 27
2024
Q4 		$1.12M Buy
106,007
+7,367
+7% +$103K 0.75% 38
2024
Q3 		$1.43M Sell
98,640
-138,297
-58% -$1.64M 0.84% 38
2024
Q2 		$2.02M Buy
236,937
+32,500
+16% +$288K 0.82% 37
2024
Q1 		$2.09M Sell
204,437
-150,204
-42% -$1.12M 0.82% 38
2023
Q4 		$1.94M Sell
354,641
-694,550
-66% -$3.04M 0.84% 46
2023
Q3 		$3.97M Sell
1,049,191
-206,449
-16% -$1.36M 0.77% 56
2023
Q2 		$8.41M Buy
1,255,640
+462,053
+58% +$3.08M 1.4% 23
2023
Q1 		$5.17M Buy
793,587
+11,177
+1% +$85.9K 0.99% 45
2022
Q4 		$6.67M Sell
782,410
-262,824
-25% -$1.71M 1.29% 26
2022
Q3 		$5.52M Buy
+1,045,234
New +$5.15M 1.09% 38

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Sectoral Asset Management's SPRY Position: Q2 2026 in Review

Sectoral Asset Management reduced its ARS Pharmaceuticals (SPRY) stake by 62% in Q2 2026, selling an estimated $424K and leaving 29,900 shares worth $239K. The position accounts for 0.17% of the portfolio, ranked #76.

Sectoral Asset Management first reported a position in SPRY in Q3 2022 and has held it in 16 quarters since. The position peaked at $8.41M in Q2 2023. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Sectoral Asset Management held 29,900 shares of ARS Pharmaceuticals worth $239K as of Q2 2026.
  • Sectoral Asset Management sold 49,250 ARS Pharmaceuticals shares in Q2 2026, an estimated $424K.
  • ARS Pharmaceuticals made up 0.17% of Sectoral Asset Management's portfolio in Q2 2026, its #76 holding.
  • Sectoral Asset Management first reported a position in ARS Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Sectoral Asset Management's ARS Pharmaceuticals position peaked at $8.41M in Q2 2023.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.